REGN-EB3: First Approval

REGN-EB3 (INMAZEB(®), Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in th...

Descripción completa

Detalles Bibliográficos
Autor principal: Markham, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799152/
https://www.ncbi.nlm.nih.gov/pubmed/33432551
http://dx.doi.org/10.1007/s40265-020-01452-3
Descripción
Sumario:REGN-EB3 (INMAZEB(®), Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in the Democratic Republic of Congo, REGN-EB3 was recently approved by the US FDA as a treatment for Ebola virus infection. This article summarizes the milestones in the development of REGN-EB3 leading to this first approval for the treatment of infection caused by Zaire ebolavirus (Ebola virus) in adult and paediatric patients.

Ejemplares similares